stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Return on assets
Insmed, Inc.'s return on assets over the twelve months to 30 September 2026 was −26.4%, up 33.1 percentage points from fiscal 2025 (−59.5%). Over the past ten years it has ranged from −60.8% (fiscal 2018) to −33.2% (fiscal 2022); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −59.5% | (5.06) |
| FY2024 | −54.5% | (4.27) |
| FY2023 | −50.2% | (16.99) |
| FY2022 | −33.2% | 9.41 |
| FY2021 | −42.6% | (4.39) |
| FY2020 | −38.2% | (0.46) |
| FY2019 | −37.8% | 23.04 |
| FY2018 | −60.8% | (5.77) |
| FY2017 | −55.0% | 4.26 |
| FY2016 | −59.3% | (19.06) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S compare | 44.3% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 41.3% |
| EXEL Exelixis, Inc. compare | 33.2% |
| GMAB Genmab A/S Sponsored ADR compare | 8.30% |
| INCY Incyte Corporation compare | 5.92% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| BNTX BioNTech SE Sponsored ADR compare | −7.22% |
| INSM Insmed, Inc. | −26.4% |
| BBIO BridgeBio Pharma, Inc. compare | −37.5% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement